H7N9 live attenuated influenza vaccine in healthy adults: A randomised, double-blind, placebo-controlled, phase 1 trial

The Lancet Infectious Diseases

Volumn 16, Issue 3, 2016, Pages 303-310

  Rudenko, Larisa ^a   Isakova Sivak, Irina ^a   Naykhin, Anatoly ^a   Kiseleva, Irina ^a   Stukova, Marina ^b   Erofeeva, Mariana ^b   Korenkov, Daniil ^a   Matyushenko, Victoria ^a   Sparrow, Erin ^c   Kieny, Marie Paule ^c  

^a INSTITUTE OF EXPERIMENTAL MEDICINE   (Russian Federation)

^b Research Institute of Influenza   (Russian Federation)

^c WORLD HEALTH ORGANIZATION   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

INFLUENZA VACCINE; NEUTRALIZING ANTIBODY; PLACEBO; LIVE VACCINE; VIRUS ANTIBODY;

ADULT; ARTICLE; BLOOD SAMPLING; CONTROLLED STUDY; COUGHING; DIZZINESS; EPISTAXIS; FEMALE; HEADACHE; HOSPITALIZATION; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; INFLUENZA A; INFLUENZA A VIRUS (H7N9); MALE; NORMAL HUMAN; NOSE DISEASE; NOSE OBSTRUCTION; NOSE SMEAR; OUTCOME ASSESSMENT; PHARYNX DISEASE; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHINORRHEA; RUSSIAN FEDERATION; SALIVA; SEROCONVERSION; SIDE EFFECT; SORE THROAT; BIOSYNTHESIS; BLOOD; CLINICAL TRIAL; DOUBLE BLIND PROCEDURE; IMMUNIZATION; IMMUNOLOGY; INFLUENZA, HUMAN; MIDDLE AGED; VIROLOGY; YOUNG ADULT;

ADULT; ANTIBODIES, VIRAL; DOUBLE-BLIND METHOD; FEMALE; HUMANS; IMMUNIZATION SCHEDULE; INFLUENZA A VIRUS, H7N9 SUBTYPE; INFLUENZA VACCINES; INFLUENZA, HUMAN; MALE; MIDDLE AGED; VACCINES, ATTENUATED; YOUNG ADULT;

EID: 84959113730     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(15)00378-3     Document Type: Article

References (33)

1. Su S, Bi Y, Wong G, Gray GC, Gao GF, Li S Epidemiology, evolution, and recent outbreaks of avian influenza virus in China. J Virol 2015, 89:8671-8676.
2. Kucharski AJ, Mills HL, Donnelly CA, Riley S Transmission potential of influenza A(H7N9) virus, China, 2013-2014. Emerg Infect Dis 2015, 21:852-855.
3. Shi Y, Zhang W, Wang F, et al. Structures and receptor binding of hemagglutinins from human-infecting H7N9 influenza viruses. Science 2013, 342:243-247.
4. Zhou J, Wang D, Gao R, et al. Biological features of novel avian influenza A (H7N9) virus. Nature 2013, 499:500-503.
5. Belser JA, Gustin KM, Pearce MB, et al. Pathogenesis and transmission of avian influenza A (H7N9) virus in ferrets and mice. Nature 2013, 501:556-559.
6. Herfst S, Imai M, Kawaoka Y, Fouchier RA Avian influenza virus transmission to mammals. Curr Top Microbiol Immunol 2014, 385:137-155.
7. Gillman A, Nykvist M, Muradrasoli S, et al. Influenza A(H7N9) acquires resistance related NA-I222T substitution when infected mallards are exposed to low levels of oseltamivir in water. Antimicrob Agents Chemother 2015, 59:5196-5202.
8. Itoh Y, Shichinohe S, Nakayama M, et al. Emergence of H7N9 influenza A virus resistant to neuraminidase inhibitors in nonhuman primates. Antimicrob Agents Chemother 2015, 59:4962-4973.
9. Hayden FG, Howard WA, Palkonyay L, Kieny MP Report of the 5th meeting on the evaluation of pandemic influenza prototype vaccines in clinical trials: World Health Organization, Geneva, Switzerland, 12-13 February 2009. Vaccine 2009, 27:4079-4089.
10. Bardiya N, Bae JH Influenza vaccines: recent advances in production technologies. Appl Microbiol Biotechnol 2005, 67:299-305.
11. Jin H, Subbarao K Live attenuated influenza vaccine. Influenza pathogenesis and control 2015, vol II:181-204. Springer International Publishing, Cham, Switzerland. M.B.A. Oldstone, R.W. Compans (Eds.).
12. Tamura S, Tanimoto T, Kurata T Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis 2005, 58:195-207.
13. Isakova-Sivak I, Chen LM, Matsuoka Y, et al. Genetic bases of the temperature-sensitive phenotype of a master donor virus used in live attenuated influenza vaccines: A/Leningrad/134/17/57 (H2N2). Virology 2011, 412:297-305.
14. Isakova-Sivak I, Stukova M, Erofeeva M, et al. H2N2 live attenuated influenza vaccine is safe and immunogenic for healthy adult volunteers. Hum Vaccin Immunother 2015, 11:970-982.
15. Rudenko L, Kiseleva I, Naykhin AN, et al. Assessment of human immune responses to H7 avian influenza virus of pandemic potential: results from a placebo-controlled, randomized double-blind phase I study of live attenuated H7N3 influenza vaccine. PLoS One 2014, 9:e87962.
16. WHO manual on animal influenza diagnosis and surveillance WHO, (accessed Oct 21, 2015). http://www.who.int/csr/resources/publications/influenza/whocdscsrncs20025rev.pdf.
17. Rowe T, Abernathy RA, Hu-Primmer J, et al. Detection of antibody to avian influenza A (H5N1) virus in human serum by using a combination of serologic assays. J Clin Microbiol 1999, 37:937-943.
18. Faul F, Erdfelder E, Buchner A, Lang AG Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods 2009, 41:1149-1160.
19. Rudenko L, Isakova-Sivak I Pandemic preparedness with live attenuated influenza vaccines based on A/Leningrad/134/17/57 master donor virus. Expert Rev Vaccines 2015, 14:395-412.
20. Talaat KR, Karron RA, Callahan KA, et al. A live attenuated H7N3 influenza virus vaccine is well tolerated and immunogenic in a phase I trial in healthy adults. Vaccine 2009, 27:3744-3753.
21. Babu TM, Levine M, Fitzgerald T, et al. Live attenuated H7N7 influenza vaccine primes for a vigorous antibody response to inactivated H7N7 influenza vaccine. Vaccine 2014, 32:6798-6804.
22. Zens KD, Farber DL Memory CD4 T cells in influenza. Curr Top Microbiol Immunol 2015, 386:399-421.
23. Coelingh KL, Luke CJ, Jin H, Talaat KR Development of live attenuated influenza vaccines against pandemic influenza strains. Expert Rev Vaccines 2014, 13:855-871.
24. Rudenko L, Isakova-Sivak I, Donina S H7N3 live attenuated influenza vaccine has a potential to protect against new H7N9 avian influenza virus. Vaccine 2013, 31:4702-4705.
25. Carter DM, Bloom CE, Kirchenbaum GA, et al. Cross-protection against H7N9 influenza strains using a live-attenuated H7N3 virus vaccine. Vaccine 2015, 33:108-116.
26. Rudenko L, Naykhin A, Donina S, et al. Assessment of immune responses to H5N1 inactivated influenza vaccine among individuals previously primed with H5N2 live attenuated influenza vaccine. Hum Vaccin Immunother (in press).
27. Talaat KR, Luke CJ, Khurana S, et al. A live attenuated influenza A(H5N1) vaccine induces long-term immunity in the absence of a primary antibody response. J Infect Dis 2014, 209:1860-1869.
28. Rudenko LG, Slepushkin AN, Monto AS, et al. Efficacy of live attenuated and inactivated influenza vaccines in schoolchildren and their unvaccinated contacts in Novgorod, Russia. J Infect Dis 1993, 168:881-887.
29. Barria MI, Garrido JL, Stein C, et al. Localized mucosal response to intranasal live attenuated influenza vaccine in adults. J Infect Dis 2013, 207:115-124.
30. Fries LF, Smith GE, Glenn GM A recombinant viruslike particle influenza A (H7N9) vaccine. N Engl J Med 2013, 369:2564-2566.
31. Mulligan MJ, Bernstein DI, Winokur P, et al. Serological responses to an avian influenza A/H7N9 vaccine mixed at the point-of-use with MF59 adjuvant: a randomized clinical trial. JAMA 2014, 312:1409-1419.
32. Bart SA, Hohenboken M, Della Cioppa G, Narasimhan V, Dormitzer PR, Kanesa-Thasan N A cell culture-derived MF59-adjuvanted pandemic A/H7N9 vaccine is immunogenic in adults. Sci Transl Med 2014, 6:234ra55.
33. Rudenko L, van den Bosch H, Kiseleva I, et al. Live attenuated pandemic influenza vaccine: clinical studies on A/17/California/2009/38 (H1N1) and licensing of the Russian-developed technology to WHO for pandemic influenza preparedness in developing countries. Vaccine 2011, 29(suppl 1):A40-A44.